ReviewTranslational lung cancer research2021
Advances in molecular mechanisms of interaction between
Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- From Case Reports to Molecular Insight: Examining the Outcomes and Underlying Mechanisms of Squamous Cell Carcinoma in Breast Implant Patients-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Global morbidity and mortality of central nervous system tuberculosis: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Article
- Scars That Speak: Unraveling the Oncogenic Aftermath of Pulmonary Tuberculosis-A Narrative Review.Journal of clinical medicine · 2026Review
- From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis.Frontiers in immunology · 2026Review
- Molecular links between tuberculosis and lung cancer: pathogenesis and therapeutic challenges.Archives of microbiology · 2025Review
- Global excess tuberculosis mortality during COVID-19: a country-level modeling study of policy and development correlates.BMC public health · 2025Article
- Post-tuberculosis morbidities and their associated mortality: moving from challenges to solutions.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- New Vistas inCancers · 2025Article
- Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors.Cancer innovation · 2025Article
- Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management.Cancer reports (Hoboken, N.J.) · 2025Review
- Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria.American journal of cancer research · 2025Review
- Article
- Deciphering the Correlation between the Emergence of Lung Carcinoma Associated with Tuberculosis-related Inflammation.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Where lung cancer and tuberculosis intersect: recent advances.Frontiers in immunology · 2025Review
- Reprogramming the host: Mycobacterium tuberculosis as a silent architect of the immuno-tumoral.Frontiers in cellular and infection microbiology · 2025Review
- Dark under the Lamp: Neglected Biological Pollutants in the Environment Are Closely Linked to Lung Cancer.International journal of molecular sciences · 2024Review
- New progress of tuberculosis scar carcinoma.Cancer metastasis reviews · 2023Review
- Alterations of lung microbiota in patients with non-small cell lung cancer.Bioengineered · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe systematically review the molecular mechanism of the interaction between lung cancer (LC) and tuberculosis (TB), and put forward the existing problems in order to provide suggestions for early intervention and future research direction.
backgroundTB and LC are two global public health problems affecting human health. LC is the main cause of cancer-related death worldwide and TB is one of the leading causes of death among infectious diseases, especially in resource-poor areas. Previous studies have suggested that a history of TB may be associated with an increased risk of LC. With the improvement of LC treatment, the occurrence of pulmonary tuberculosis in the course of LC treatment is also frequently reported recently.
methodsThe molecular immunological mechanisms of interaction between LC and TB, and related epidemiological literature are reviewed. The research progress and problems to be solved are summarized.
conclusionsChronic inflammation, immune abnormalities, scar formation, gene mutations and drug effects caused by TB may be associated with the occurrence of LC induced by abnormalities in various molecular pathways. LC and decreased immunity during treatment may also increase the risk of latent TB activation or new TB infection through immune pathways. Data on dual burden areas of TB and LC are still lacking, and more clinical studies are needed to elucidate the association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.